Yes, hypothyroidism can cause facial hair growth, but it is an indirect and relatively uncommon cause. Thyroid hormone deficiency disrupts the hypothalamic-pituitary-ovarian axis, raising prolactin and shifting androgen metabolism so that testosterone converts more readily to dihydrotestosterone (DHT) in the skin. This produces a mild, diffuse, often vellus-type hair increase along the upper lip and chin rather than the coarse terminal pattern of PCOS. Roughly 2 to 6 percent of women with unexplained hirsutism have hypothyroidism as a contributing factor, and treating the thyroid alone reverses the hair change in only a minority of cases.
The androgen mechanism behind thyroid-related facial hair
Thyroid hormone does not make hair grow directly. It works upstream, by changing how the body regulates the hormones that do.
In hypothyroidism, low circulating T3 and T4 reduce hepatic sex hormone-binding globulin (SHBG) production. With less SHBG, more free testosterone circulates unbound and available to tissue. Simultaneously, thyrotropin-releasing hormone (TRH) rises, which stimulates prolactin. Elevated prolactin feeds back on the hypothalamus and suppresses gonadotropin-releasing hormone, tilting the androgen-to-estrogen balance toward androgens.
A second, less obvious mechanism matters for facial hair specifically. Thyroid hormone regulates the local enzyme 5-alpha reductase in the skin and hair follicle. In hypothyroid states this enzyme's activity is altered, and 5-alpha reductase converts testosterone to DHT, the androgen roughly five to ten times more potent at the follicle. DHT miniaturizes scalp hair and, paradoxically, thickens androgen-sensitive facial hair.
The follicle's response depends on its location and androgen sensitivity, not on the absolute hormone level alone. That is why hypothyroid facial hair tends to appear on the upper lip, chin, and jawline — the same sites that respond to androgen in PCOS — but typically at lower density.
In plain terms: the thyroid problem rarely raises total testosterone much, but it changes the hormonal environment so that the testosterone present does more damage at the follicle.
How much facial hair hypothyroidism actually causes
Quantifying the link is where most explanations stop, so here are the numbers that matter.
| Finding | Hypothyroidism | PCOS | Idiopathic hirsutism |
|---|---|---|---|
| Prevalence of hirsutism among affected women | 2–6% | 70–80% | 5–15% of all hirsutism cases |
| Typical Ferriman-Gallwey score | 8–12 (mild) | 15–25 (moderate to severe) | 8–14 |
| Predominant hair type | Vellus to thin terminal | Coarse terminal | Coarse terminal |
| Serum total testosterone | Normal or slightly low | Elevated in 50–70% | Normal |
| SHBG level | Low | Low | Normal |
| Response of hair to treating the root cause | Partial, in 20–30% | Partial, needs anti-androgen | None without cosmetic treatment |
The Ferriman-Gallwey score counts terminal hair in nine body areas, scored 0 to 4 each, with a total above 8 indicating hirsutism. A hypothyroid patient typically scores in the 8 to 12 range — above threshold, but well below the 15 to 25 range common in PCOS. That gap is the single most useful clinical clue when a clinician is deciding which condition to chase first.
Hirsutism affects roughly 5 to 10 percent of women of reproductive age overall. Hypothyroidism affects about 4.6 percent of the US population, and up to 10 percent of women over 40. Because both are common, a proportion of overlap is coincidental rather than causal.
Why thyroid hair changes look different from PCOS hair
The two conditions produce facial hair through different arms of the same system, and the texture usually gives it away.
PCOS drives ovarian and adrenal androgen production directly, pushing total testosterone up. The result is coarse, dark terminal hair appearing early — often in the teens or early twenties — alongside acne, irregular periods, and scalp thinning.
Hypothyroidism works mostly through SHBG reduction and prolactin elevation. Total testosterone is often normal. The facial hair is finer, appears more diffusely across the lip and chin, and frequently arrives alongside the classic thyroid signs: fatigue, cold intolerance, weight gain, dry skin, and constipation.
A useful clinical caveat: thyroid disease can coexist with PCOS in the same patient. Up to 25 to 30 percent of women with PCOS have elevated thyroid antibodies or subclinical hypothyroidism, so finding one does not exclude the other. When both are present, treating the thyroid may improve the androgen profile but rarely resolves hirsutism entirely.
Timeline: when facial hair changes after thyroid treatment
Patients often expect facial hair to vanish once levothyroxine is started. It does not work that way. Hair follicles cycle through anagen (growth), catagen (transition), and telogen (rest) phases, and facial follicles have a shorter cycle than scalp hair but still take months to reset.
| Time after starting levothyroxine | What happens | Expected facial hair change |
|---|---|---|
| Week 0–2 | TSH begins to fall; thyroid hormone levels rise | None |
| Week 6–8 | TSH rechecked; dose adjusted if needed | None |
| Month 2–3 | SHBG and prolactin begin normalizing | Shedding of some vellus hair may start |
| Month 3–6 | Androgen metabolism stabilizes | Partial reduction in growth rate |
| Month 6–12 | Full effect of thyroid correction on follicles | Modest thinning, rarely complete clearance |
| Month 12+ | Plateau | Residual terminal hair persists in 70–80% |
Two details are counterintuitive. First, some patients notice a temporary increase in shedding around month two to three, driven by the telogen-to-anagen shift, not by worsening disease. Second, correcting the thyroid normalizes SHBG and prolactin within six to eight weeks, but the follicle's structural change from vellus to terminal hair is only partly reversible — terminal follicles often stay terminal even after hormones normalize, which is why cosmetic treatment frequently remains necessary.
Red flags that mean something else is going on
Facial hair in a hypothyroid patient is usually mild. Certain patterns point to a separate or additional diagnosis and warrant prompt evaluation.
- Rapid onset over weeks to months, especially with voice deepening or clitoromegaly, suggests an androgen-secreting ovarian or adrenal tumor.
- Severe acne, male-pattern balding, and irregular periods appearing together point toward PCOS rather than thyroid disease.
- A Ferriman-Gallwey score above 15 in a hypothyroid patient suggests a second androgen source.
- New facial hair with unexplained weight loss, palpitations, or tremor could indicate an androgen source rather than hypothyroidism.
- Facial hair appearing before age 8 in a girl, or with growth acceleration, warrants evaluation for precocious puberty.
- Any virilization sign in a woman — temporal balding, muscle hypertrophy, breast atrophy — is a red flag for a tumor until proven otherwise.
What to actually do about thyroid-linked facial hair
The sequence matters more than any single step. Address the thyroid first, then reassess, then treat the hair itself.
Get a full thyroid panel, not just TSH. TSH alone misses central hypothyroidism and gives no information about antibody status. A complete panel includes TSH, free T4, and thyroid peroxidase (TPO) antibodies. Per the American Thyroid Association, levothyroxine is the standard replacement and TSH should be rechecked six to eight weeks after any dose change.
Optimize replacement before judging hair response. A TSH inside the reference range does not guarantee tissue-level correction in every patient, but persistent elevation above 4.0 mIU/L is a clear signal that replacement is insufficient. Do not add anti-androgen therapy until thyroid status has been stable for at least three months.
Track the hair objectively. Photograph the same facial area in consistent lighting every three months and, if a clinician is involved, record a Ferriman-Gallwey score at baseline and follow-up. Subjective impressions of hair growth are unreliable over short intervals.
Use cosmetic measures in parallel, not as a last resort. Electrolysis and laser hair removal work on terminal hair regardless of cause. Spironolactone, at 50 to 100 mg daily, blocks androgen receptors and is the standard add-on when hirsutism persists after thyroid correction, but it is not appropriate in pregnancy and requires monitoring.
Do not expect monotherapy to solve a multifactorial problem. Roughly 20 to 30 percent of patients see meaningful facial hair improvement from thyroid correction alone. The majority need a combined approach.
Limitations of the evidence and where certainty ends
The link between hypothyroidism and facial hair rests largely on mechanistic reasoning and small observational studies, not large randomized trials. No trial has randomized hypothyroid women to levothyroxine versus placebo and measured Ferriman-Gallwey scores as a primary endpoint, so the causal strength is moderate at best.
Several confounders muddy the picture. Age, body mass index, and menopausal status all shift both thyroid function and androgen metabolism. Many hypothyroid patients are also older, and facial vellus hair increases naturally with age and estrogen decline, which can be mistaken for androgen-driven growth.
The prevalence figures of 2 to 6 percent come from hirsutism clinic cohorts, which are enriched for severe cases and may not generalize. A primary care population with mild hypothyroidism would likely show a lower attributable fraction.
Finally, individual response to thyroid replacement varies with genetics of the 5-alpha reductase enzyme, baseline follicle sensitivity, and how long the hypothyroidism went untreated. A patient diagnosed after ten years of subclinical disease may have more entrenched terminal follicles than one caught at six months. The honest clinical position is that hypothyroidism is a real but modest contributor to facial hair growth — worth ruling out in any woman with new facial hair and thyroid symptoms, but rarely the whole explanation.